1509899-61-9

Usage

Uses

Used in Organic Synthesis:
(R)-1-(7-bromoquinolin-2-yl)ethan-1-ol is used as a building block in the organic synthesis industry for the creation of more complex molecules. Its unique structure, including the bromine-substituted quinoline ring and chiral center, allows for a range of reactions that can lead to novel compounds with specific properties and applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (R)-1-(7-bromoquinolin-2-yl)ethan-1-ol is used as a starting material for the development of new drugs. Its chirality and chemical structure make it a promising candidate for the synthesis of enantiomerically pure compounds, which are often required for the desired biological activity and to avoid potential side effects associated with the less active enantiomer.
Used in Chemical Research:
(R)-1-(7-bromoquinolin-2-yl)ethan-1-ol is also utilized in the chemical research field as a model compound to study the effects of stereochemistry on reactivity and the development of new synthetic methods. Understanding how (R)-1-(7-bromoquinolin-2-yl)ethan-1-ol reacts under various conditions can provide insights into the broader field of asymmetric synthesis and the creation of enantiomerically enriched products.

Upstream product

• 1509899-60-8 1-(7-bromoquinolin-2-yl)ethan-1-one 
• 99455-15-9 7-bromo-2-chloro-quinoline 

Relevant academic research and scientific papers

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

Cyclophilins are a family of peptidyl-prolyl isomerases that are implicated in a wide range of diseases including hepatitis C. Our aim was to discover through total synthesis an orally bioavailable, non-immunosuppressive cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus (HCV) activity that could serve as part of an all oral antiviral combination therapy. An initial lead 2 derived from the sanglifehrin A macrocycle was optimized using structure based design to produce a potent and orally bioavailable inhibitor 3. The macrocycle ring size was reduced by one atom, and an internal hydrogen bond drove improved permeability and drug-like properties. 3 demonstrates potent Cyp inhibition (Kd = 5 nM), potent anti-HCV 2a activity (EC50 = 98 nM), and high oral bioavailability in rat (100%) and dog (55%). The synthetic accessibility and properties of 3 support its potential as an anti-HCV agent and for interrogating the role of Cyp inhibition in a variety of diseases.

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.